Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. PIMA541843

Invitrogen™ Canakinumab Recombinant Human Monoclonal Antibody
GREENER_CHOICE

Catalog No. PIMA541843
Change view
Click to view available options
Quantity:
100 μg
Catalog No. Quantity
PIMA541843 100 μg
1 options
This item is not returnable. View return policy

Catalog No. PIMA541843

Supplier: Invitrogen™ MA541843

Only null left
Add to Cart
Add to Cart
This item is not returnable. View return policy

Description

Human Recombinant Monoclonal Antibody

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Canakinumab is a recombinant, human anti-human-IL-1beta monoclonal antibody that belongs to the IgG1/kappa isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn298). Canakinumab binds to human IL-1beta and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients.
TRUSTED_SUSTAINABILITY

Specifications

Antigen Canakinumab
Applications ELISA, SDS-Page
Classification Recombinant Monoclonal
Concentration 1.94 mg/mL
Conjugate Unconjugated
Formulation PBS with no preservative; pH 7.4
Gene Alias ACZ885
Host Species Human
Immunogen Human IL1B.
Purification Method Protein A/G
Quantity 100 μg
Regulatory Status RUO
Primary or Secondary Primary
Target Species Human
Content And Storage -20°C, Avoid Freeze/Thaw Cycles
Product Type Antibody
Form Liquid
Isotype IgG1 κ
Target Molecule Chemical
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.